---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-105729"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2022-04-14T23:59:59+00:00"
generated_at: "2026-06-26T07:26:12.145861+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology CSO Ronald Herbst resigns; Jan Pinkas promoted to CSO

## Summary
- Ronald Herbst, Ph.D. resigned as CSO effective April 12, 2022; Mark Chin resigned from Board same day.
- Jan Pinkas, Ph.D., formerly SVP Preclinical R&D, promoted to CSO effective April 12, 2022.
- Company reaffirms IND filings for PYX-201 (Anti-EDB) and PYX-106 (Anti-Siglec-15) expected in 2H22.
- Neither departure was due to any disagreement with the company or Board.

## SEC filing metadata
- accession: 0001193125-22-105729
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2022-04-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/0001193125-22-105729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/d331497d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-105729
- JSON: https://secwatch.observer/filing/0001193125-22-105729.json
- Plain text: https://secwatch.observer/filing/0001193125-22-105729.txt

## Key facts
- Executive change
  Ronald Herbst resigned as Chief Scientific Officer at Pyxis Oncology, Inc..
  - Action: resigned
  - Role: Chief Scientific Officer
  source text: On April 8, 2022, Ronald Herbst, Ph.D. resigned from his position with Pyxis Oncology, Inc. (the “Company”) as Chief Scientific Officer, effective on April 12, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/0001193125-22-105729-index.htm
- Executive change
  Mark Chin resigned as Director at Pyxis Oncology, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 12, 2022, Mark Chin resigned from his position as a director of the board of directors (the “Board”) of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000119312522105729/0001193125-22-105729-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.